Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Reappraising the use of β-lactams to treat tuberculosis.

Literature DB >> 23106275

Reappraising the use of β-lactams to treat tuberculosis.

Abstract

The emergence of multidrug-resistant and extensively drug-resistant tuberculosis calls for novel approaches to treatment. Recent studies have shown that BlaC, the β-lactamase of Mycobacterium tuberculosis, is the major determinant of β-lactam resistance. This review invites the reader to explore evidence in order to answer the questions: can β-lactam and β-lactamase inhibitors adequately treat M. tuberculosis infection and are they a viable option in the management of resistant tuberculosis today?

Entities: Chemical Disease Gene Species

Mesh：

Substances：

Year: 2012 PMID： 23106275 PMCID： PMC3728824 DOI： 10.1586/eri.12.96

Source DB: PubMed Journal: Expert Rev Anti Infect Ther ISSN： 1478-7210 Impact factor: 5.091

53 in total

Review 1. Biochemistry and comparative genomics of SxxK superfamily acyltransferases offer a clue to the mycobacterial paradox: presence of penicillin-susceptible target proteins versus lack of efficiency of penicillin as therapeutic agent.

Authors: Colette Goffin; Jean-Marie Ghuysen
Journal: Microbiol Mol Biol Rev Date: 2002-12 Impact factor: 11.056

2. Crystal structure and activity studies of the Mycobacterium tuberculosis beta-lactamase reveal its critical role in resistance to beta-lactam antibiotics.

Authors: Feng Wang; Craig Cassidy; James C Sacchettini
Journal: Antimicrob Agents Chemother Date: 2006-08 Impact factor: 5.191

3. Beta-lactamase activity in mycobacteria other than M. tuberculosis.

Authors: A Coira; M Salvadó; R Reig; J Chaves; C Segura
Journal: J Chemother Date: 1995-04 Impact factor: 1.714

4. The synergistic effect of dicloxacillin and penicillin G on murine tuberculosis.

Authors: J E Kasik; M Weber; E Winberg; W R Barclay
Journal: Am Rev Respir Dis Date: 1966-08

5. Meropenem/clavulanate and linezolid treatment for extensively drug-resistant tuberculosis.

Authors: Nicolas Dauby; Inge Muylle; Françoise Mouchet; Roger Sergysels; Marie-Christine Payen
Journal: Pediatr Infect Dis J Date: 2011-09 Impact factor: 2.129

6. Role of penicillin-binding protein 5 in expression of ampicillin resistance and peptidoglycan structure in Enterococcus faecium.

Authors: F Sifaoui; M Arthur; L Rice; L Gutmann
Journal: Antimicrob Agents Chemother Date: 2001-09 Impact factor: 5.191

7. Recombinant expression and characterization of the major beta-lactamase of Mycobacterium tuberculosis.

Authors: R K Voladri; D L Lakey; S H Hennigan; B E Menzies; K M Edwards; D S Kernodle
Journal: Antimicrob Agents Chemother Date: 1998-06 Impact factor: 5.191

8. Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate.

Authors: Lee W Tremblay; Jean-Emmanuel Hugonnet; John S Blanchard
Journal: Biochemistry Date: 2008-04-19 Impact factor: 3.162

Review 9. The envelope of mycobacteria.

Authors: P J Brennan; H Nikaido
Journal: Annu Rev Biochem Date: 1995 Impact factor: 23.643

Review 10. AmpC beta-lactamases.

Authors: George A Jacoby
Journal: Clin Microbiol Rev Date: 2009-01 Impact factor: 26.132

16 in total

Review 1. A Structure-Based Classification of Class A β-Lactamases, a Broadly Diverse Family of Enzymes.

Authors: Alain Philippon; Patrick Slama; Paul Dény; Roger Labia
Journal: Clin Microbiol Rev Date: 2016-01 Impact factor: 26.132

2. β-Lactamase of Mycobacterium tuberculosis Shows Dynamics in the Active Site That Increase upon Inhibitor Binding.

Authors: Wouter Elings; Anamika Gaur; Anneloes J Blok; Monika Timmer; Hugo van Ingen; Marcellus Ubbink
Journal: Antimicrob Agents Chemother Date: 2020-02-21 Impact factor: 5.191

3. Dual-Pharmacophore Pyrithione-Containing Cephalosporins Kill Both Replicating and Nonreplicating Mycobacterium tuberculosis.

Authors: Landys Lopez Quezada; Kelin Li; Stacey L McDonald; Quyen Nguyen; Andrew J Perkowski; Cameron W Pharr; Ben Gold; Julia Roberts; Kathrine McAulay; Kohta Saito; Selin Somersan Karakaya; Prisca Elis Javidnia; Esther Porras de Francisco; Manuel Marin Amieva; Sara Palomo Dı Az; Alfonso Mendoza Losana; Matthew Zimmerman; Hsin-Pin Ho Liang; Jun Zhang; Veronique Dartois; Stéphanie Sans; Sophie Lagrange; Laurent Goullieux; Christine Roubert; Carl Nathan; Jeffrey Aubé
Journal: ACS Infect Dis Date: 2019-06-11 Impact factor: 5.084

4. Susceptibilities of MDR Mycobacterium tuberculosis isolates to unconventional drugs compared with their reported pharmacokinetic/pharmacodynamic parameters.

Authors: Joseph S Cavanaugh; Ruwen Jou; Mei-Hua Wu; Tracy Dalton; Ekaterina Kurbatova; Julia Ershova; J Peter Cegielski
Journal: J Antimicrob Chemother Date: 2017-06-01 Impact factor: 5.790

5. Combinatorial active-site variants confer sustained clavulanate resistance in BlaC β-lactamase from Mycobacterium tuberculosis.

Authors: Philippe Egesborg; Hélène Carlettini; Jordan P Volpato; Nicolas Doucet
Journal: Protein Sci Date: 2014-12-30 Impact factor: 6.725

6. Kinetic characterization of hydrolysis of nitrocefin, cefoxitin, and meropenem by β-lactamase from Mycobacterium tuberculosis.

Authors: Carmen Chow; Hua Xu; John S Blanchard
Journal: Biochemistry Date: 2013-05-30 Impact factor: 3.162